Oxurion NV announced the appointment of Grace Chang, M.D., Ph.D. as the company’s Chief Medical Officer, effective August 1, 2020. Dr. Chang is a board-certified ophthalmologist and practicing vitreoretinal surgeon with deep expertise in ophthalmic drug research and development. She will be responsible for leading the Company’s clinical programs for both THR-687 and THR-149 as Oxurion looks to build a diabetic macular edema (DME) franchise that could provide much improved therapeutic solutions for all DME patients. Dr. Chang joins Oxurion from Notal Vision Inc, where she held the position of CMO and was responsible for the scientific and clinical strategy, clinical development and medical affairs programs. She is currently an Adjunct Clinical Associate Professor in the Department of Ophthalmology, Vitreoretinal Service at the University of Southern California in Los Angeles, CA. Prior to this, Dr. Chang held several high-level clinical and strategic roles at Alcon Laboratories, a former subsidiary of Novartis, following a faculty appointment at the University of Washington.